|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-19
|
|
pubmed:abstractText |
This prospective study is designed to examine the effects of severe renal failure on the pharmacokinetics of irinotecan. The pharmacokinetics of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), and SN-38 glucuronide (SN-38G) in three cancer patients with severe renal failure [creatinine clearance (Ccr) ? 20 ml/min] who were undergoing dialysis and received 100 mg/m(2) irinotecan as monotherapy were prospectively compared with those in five cancer patients with normal renal function (Ccr ? 60 ml/min). To ensure that the subjects had similar genetic backgrounds of UDP-glucuronosyltransferase (UGT) 1A1, patients with UGT1A1*1/*1, *1/*6, or *1/*28 were enrolled. The estimated terminal elimination rate constant of SN-38 in patients undergoing dialysis was approximately one tenth of that in patients with normal renal function (P = 0.025). Approximately 50% of SN-38 was dialyzed with a 2.1-m(2) dialysis membrane, whereas 27% was dialyzed with a 1.5-m(2) membrane. Our results showed that the elimination of SN-38 was significantly delayed in patients with severe renal failure compared with patients with normal renal function. We demonstrated that SN-38 was partly dialyzed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1521-009X
|
|
pubmed:author |
pubmed-author:AkiyamaYukoY,
pubmed-author:AndoYuichiY,
pubmed-author:FujitaKen-ichiK,
pubmed-author:HiroseTakashiT,
pubmed-author:IchikawaWataruW,
pubmed-author:IshidaHirooH,
pubmed-author:KawaraKaoriK,
pubmed-author:MiwaKeisukeK,
pubmed-author:MiyaToshimichiT,
pubmed-author:MizunoKeikoK,
pubmed-author:NagashimaFumioF,
pubmed-author:NarabayashiMasaruM,
pubmed-author:SajiShigehiraS,
pubmed-author:SasakiYasutsunaY,
pubmed-author:SugiyamaMinakoM,
pubmed-author:SunakawaYuY,
pubmed-author:YamamotoWataruW,
pubmed-author:YamashitaKeishiK
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
161-4
|
|
pubmed:meshHeading |
pubmed-meshheading:20980446-Aged,
pubmed-meshheading:20980446-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:20980446-Camptothecin,
pubmed-meshheading:20980446-Female,
pubmed-meshheading:20980446-Genotype,
pubmed-meshheading:20980446-Glucuronides,
pubmed-meshheading:20980446-Glucuronosyltransferase,
pubmed-meshheading:20980446-Humans,
pubmed-meshheading:20980446-Male,
pubmed-meshheading:20980446-Metabolic Clearance Rate,
pubmed-meshheading:20980446-Middle Aged,
pubmed-meshheading:20980446-Neoplasms,
pubmed-meshheading:20980446-Prospective Studies,
pubmed-meshheading:20980446-Renal Dialysis,
pubmed-meshheading:20980446-Renal Insufficiency
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Delayed elimination of SN-38 in cancer patients with severe renal failure.
|
|
pubmed:affiliation |
Department of Medical Oncology, International Medical Center-Comprehensive Cancer Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan. fujitak@saitama-med.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
